Compounded Semaglutide Weight Loss Program

About this program

A physician-supervised weight management program built around compounded semaglutide, a GLP-1 receptor agonist. Includes clinical review by a licensed U.S. provider, the prescribed medication dispensed by a licensed U.S. compounding pharmacy, dose adjustments during treatment, ongoing access to your care team, and free tracked shipping. Prescription required; eligibility is determined by a licensed provider. Available to adults in the United States only.

How semaglutide works

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone the gut releases after eating, and acts on three fronts: it slows how quickly the stomach empties, signals fullness to the appetite centres in the brain, and prompts the pancreas to release insulin when blood glucose rises.

The practical effect most patients notice first is a reduction in appetite and in the persistent food preoccupation often described as "food noise". Because gastric emptying slows, meals feel satisfying for longer and portions tend to fall without deliberate restriction.

What the clinical evidence shows

Semaglutide 2.4 mg weekly was studied for weight management in the STEP trial programme. In STEP 1, adults with overweight or obesity and without diabetes received weekly semaglutide or placebo alongside lifestyle intervention over 68 weeks; the semaglutide group lost substantially more weight than placebo.

Two caveats matter more than the headline figures. Trial participants received structured diet and activity counselling throughout, so the medication was never studied as a standalone intervention. And individual response varies widely — a trial average describes a population, not what any one person should expect.

Dosing and titration

Semaglutide is a once-weekly subcutaneous injection. Treatment starts at a low dose and increases gradually over several months. That ramp is deliberate: it gives the digestive system time to adapt and reduces the intensity of early side effects.

Escalating faster than prescribed does not accelerate results — it mostly intensifies nausea. Your prescribing provider sets the schedule and adjusts it based on how you respond and tolerate each step. Dose changes are included in the monthly price; the cost does not rise as your dose does.

Side effects and safety

The most common side effects are gastrointestinal and usually most noticeable in the first weeks and after each dose increase:

• Nausea
• Diarrhoea or constipation
• Vomiting
• Abdominal pain
• Reduced appetite

These typically ease as the body adapts, and are the most common reason people stop treatment early. Tell your care team early rather than stopping on your own — a slower titration often resolves them.

More serious risks include pancreatitis, gallbladder disease, kidney problems from dehydration, and thyroid C-cell tumours observed in rodent studies. Semaglutide is not appropriate for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your medical intake screens for these; disclose your full history, including all medications and supplements.

Semaglutide compared with tirzepatide

Semaglutide targets the GLP-1 receptor alone. Tirzepatide targets GLP-1 and GIP, a second incretin receptor, and produced greater average reduction in its own trial programme. They were studied separately, however, not head to head, and greater average effect does not make one the right choice for a given person.

Which is appropriate depends on medical history, other medications, prior treatment response and tolerance for side effects — a clinical decision your provider makes with you. Read the full comparison.

Eligibility

• Adults 18 years or older, residing in the United States.
• Requires completion of a medical intake and review by a licensed provider.
• A prescription is issued only if a provider determines treatment is appropriate. Not all applicants qualify.
• A synchronous telehealth consultation may be required depending on your state.